FDA publishes guidance in non-opioid pain management

CBER Director Vinay Prasad sidelined staff to jettison Moderna’s mRNA flu shot

In the latest episode of Vinay Prasad’s extraordinary adventures at FDA, the agency (i.e. Dr. Prasad himself) has issued a Refusal-to-File letter to an mRNA-based influenza vaccine application.

February 13, 2026

Vol.52 No.06

By Claire Marie Porter

Cancer Policy

FDA approves labeling changes to menopausal hormone therapy products

FDA has approved drug labeling changes to six menopausal hormone therapy products, also known as hormone replacement therapy.

February 13, 2026

Vol.52 No.06

By Claire Marie Porter

Drugs & Targets

FDA approves pembrolizumab with paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma

FDA approved pembrolizumab, as well as pembrolizumab and berahyaluronidase alfa-pmph in combination with paclitaxel, with or without bevacizumab, for adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS≥1) as determined by an FDA-authorized test, and who have received one or two prior systemic treatment regimens.

February 13, 2026

Vol.52 No.06

Drugs & Targets

FDA approves companion diagnostic for pembrolizumab for ovarian cancer

FDA has approved PD-L1 IHC 22C3 pharmDx, Code SK006m as the only FDA-approved companion diagnostic indicated to aid in identifying first-line patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, whose tumors express PD-L1 and who may be eligible for treatment with Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy.

February 13, 2026

Vol.52 No.06

Cancer Policy

FDA debuts precheck manufacturing program to boost domestic drug development

FDA has launched a venture in onshoring domestic drug development called the Precheck Pilot Program.

February 06, 2026

Vol.52 No.05

By Claire Marie Porter

Clinical Roundup

Oral cancer pain and opioid tolerance share underlying process, study finds

Epidermal growth factor receptor signaling in the tissue around oral cancers both increases nerve sensitivity and makes opioids less effective, according to a study conducted by researchers at NYU, MD Anderson, and Loma Linda University. The finding points to a shared mechanism underlying both oral cancer pain and opioid tolerance, and a possible new treatment strategy for both.

February 06, 2026

Vol.52 No.05

FDA publishes guidance in non-opioid pain management

YOU MAY BE INTERESTED IN

CBER Director Vinay Prasad sidelined staff to jettison Moderna’s mRNA flu shot

FDA approves labeling changes to menopausal hormone therapy products

FDA approves pembrolizumab with paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma

FDA approves companion diagnostic for pembrolizumab for ovarian cancer

FDA debuts precheck manufacturing program to boost domestic drug development

Oral cancer pain and opioid tolerance share underlying process, study finds

Renew today!

Subscriber content

Never miss an issue!

Login